122
Commentary on “70 Gy vs. 80 Gy in localized prostate cancer: 5-Year results of GETUG 06 randomized trial.” Beckendorf V, Guerif S, Le Prisé E, Cosset JM, Bougnoux A, Chauvet B, Salem N, Chapet O, Bourdain S, Bachaud JM, Maingon P, Hannoun-Levi JM, Malissa123
Commentary on “A comparison of outcomes for interfascial and intrafascial nerve-sparing radical prostatectomy”: Stolzenburg JU, Kallidonis P, Do M, Dietel A, Häfner T, Rabenalt R, Sakellaropoulos G, Ganzer R, Paasch U, Horn LC, Liatsikos E, Department of128
Commentary on “A non-cancer-related survival benefit is associated with partial nephrectomy.” Sun M, Trinh QD, Bianchi M, Hansen J, Hanna N, Abdollah F, Shariat SF, Briganti A, Montorsi F, Perrotte P, Karakiewicz PI, Cancer Prognostics and Health Outcomes136
Commentary on “Abiraterone in metastatic prostate cancer without previous chemotherapy.” Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijv137
Commentary on “Abiraterone in metastatic prostate cancer without previous chemotherapy.” Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijv139
Commentary on “Adverse prognostic factors for testicular cancer-specific survival: A population-based study of 27,948 patients.” Fosså SD, Cvancarova M, Chen L, Allan AL, Oldenburg J, Peterson DR, Travis LB, Oslo University Hospital, University of Oslo, N144
Commentary on “Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): A randomised, open-label, phase 3 trial.” Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakow145
Commentary on “Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): A randomised, open-label, phase 3 trial.” Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakow155
Commentary on “Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.” Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan156
Commentary on “Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.” Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan159
Commentary on “Circulating angiostatin, bFGF, and Tie2/TEK levels and their prognostic impact in bladder cancer.” Szarvas T, Jäger T, Laszlo V, Kramer G, Klingler HC, vom Dorp F, Romics I, Ergün S, Rübben H, Department of Urology, University of Duisburg-E161
Commentary on “Common Genetic Polymorphisms Modify the Effect of Smoking on Absolute Risk of Bladder Cancer.” Garcia-Closas M, Rothman N, Figueroa JD, Prokunina-Olsson L, Han SS, Baris D, Jacobs EJ, Malats N, De Vivo I, Albanes D, Purdue MP, Sharma S, Fu164
Commentary on “Comparative effectiveness of cryotherapy vs. brachytherapy for localized prostate cancer.” Williams SB, Lei Y, Nguyen PL, Gu X, Lipsitz SR, Yu HY, Kowalczyk KJ, Hu JC, Division of Urologic Surgery, Department of Radiation Oncology, Center f178
Commentary on “Detailed analysis of morbidity following nephrectomy for renal cell carcinoma in octogenarians.” Berger J, Fardoun T, Brassart E, Capon G, Bigot P, Bernhard JC, Rigaud J, Patard JJ, Descazeaud A, Department of Urology, Dupuytren University179
Commentary on “Detailed analysis of morbidity following nephrectomy for renal cell carcinoma in octogenarians.” Berger J, Fardoun T, Brassart E, Capon G, Bigot P, Bernhard JC, Rigaud J, Patard JJ, Descazeaud A, Department of Urology, Dupuytren University185
Commentary on “Dynamic real-time microscopy of the urinary tract using confocal laser endomicroscopy.” Wu K, Liu JJ, Adams W, Sonn GA, Mach KE, Pan Y, Beck AH, Jensen KC, Liao JC, Department of Urology, Stanford Cancer Center, Stanford University School o190
Commentary on “Effects of prostate-specific antigen testing on familial prostate cancer risk estimates”: Bratt O, Garmo H, Adolfsson J, Bill-Axelson A, Holmberg L, Lambe M, Stattin P, Department of Urology, Helsingborg Hospital, Helsingborg, Sweden. J Nat192
Commentary on “ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients.” Baena E, Shao Z, Linn DE, Glass K, Hamblen MJ, Fujiwara Y, Kim J, Nguyen M, Zhang X, Godinho FJ, Bronson RT, Mucci LA, Loda M, Yuan GC,198
Commentary on “Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival”. Nguyen PL, Ma J, Chavarro JE, Freedman ML, Lis R, Fedele G, Fiore C, Qiu W, Fiorentino M, Finn S, Penney KL, Eisenstein A, Schumacher199
Commentary on “Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery.” Silberstein JL, Millard F, Mehrazin R, Kopp R, Bazzi W, DiBlasio CJ, Patterson AL, Downs TM, Yunus F, Kane CJ, Derweesh IH, Division of Urology, Department o211
Commentary on “Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array.” Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S,213
Commentary on “Impact of body mass index on perioperative morbidity, oncological, and functional outcomes after extraperitoneal laparoscopic radical prostatectomy.” Campeggi A, Xylinas E, Ploussard G, Ouzaid I, Fabre A, Allory Y, Vordos D, Abbou CC, Salom214
Commentary on “Impact of body mass index on perioperative morbidity, oncological, and functional outcomes after extraperitoneal laparoscopic radical prostatectomy.” Campeggi A, Xylinas E, Ploussard G, Ouzaid I, Fabre A, Allory Y, Vordos D, Abbou CC, Salom215
Commentary on “Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death”. Choueiri TK, Chen MH, DʹAmico AV, Sun L, Nguyen PL, Hayes JH, Robertson CN, Walther PJ, Polascik TJ, Albala DM, Moul220
Commentary on “Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer.” Weischenfeldt J, Simon R, Feuerbach L, Schlangen K, Weichenhan D, Minner S, Wuttig D, Warnatz HJ, Stehr H, Rausch T, Jäger221
Commentary on “Intermittent versus continuous androgen deprivation in prostate cancer.” Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN,222
Commentary on “Intermittent versus continuous androgen deprivation in prostate cancer.” Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN,223
Commentary on “Intermittent versus continuous androgen deprivation in prostate cancer.” Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN,233
Commentary on “Locally advanced prostate cancer: A population-based study of treatment patterns”. W.T. Lowrance, E.B. Elkin, D.S. Yee, A. Feifer, B. Ehdaie, L.M. Jacks, C.L. Atoria, M.J. Zelefsky, H.I. Scher, P.T. Scardino, J.A. Eastham, Department of Sur236
Commentary on “Management of rectal injury during robotic radical prostatectomy.” Kheterpal E, Bhandari A, Siddiqui S, Pokala N, Peabody J, Menon M, Vattikuti Urology Institute, Henry Ford Health System, Henry Ford Hospital, Detroit, Michigan: Urology 201241
Commentary on “Mortality results from the Göteborg randomized population-based prostate-cancer screening trial”: Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, Pihl CG, Stranne J, Holmberg E, Lilja H, Department of Urology, Institute of243
Commentary on “Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: A phase II study”. Pagliaro LC, Williams DL, Daliani D, Williams MB, Osai W, Kincaid M, Wen S, Thall PF, Pettaway CA, Department of Genitourinary M251
Commentary on “Outcomes of robotic partial nephrectomy for renal masses with nephrometry score of ≥7.” White MA, Haber GP, Autorino R, Khanna R, Hernandez AV, Forest S, Yang B, Altunrende F, Stein RJ, Kaouk JH, Department of Surgery, Center for Laparoscop252
Commentary on “Paclitaxel gelatin nanoparticles for intravesical bladder cancer therapy.” Lu Z, Yeh TK, Wang J, Chen L, Lyness G, Xin Y, Wientjes MG, Bergdall V, Couto G, Alvarez-Berger F, Kosarek CE, Au JL, Optimum Therapeutics, L.L.C., Columbus, OH: J U256
Commentary on “Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer.” Gray PJ, Paly JJ, Yeap BY, Sanda MG, Sandler HM, Michalski JM, Talcott JA, Coen JJ, Hamstra DA, Shiple261
Commentary on “Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma.” Wong YN, Litwin S, Vaughn D, Cohen S, Plimack ER, Lee J, Song W, Dabrow M, Brody M, Tuttle H, Hudes G, University of Pennsylvania,262
Commentary on “Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma.” Wong YN, Litwin S, Vaughn D, Cohen S, Plimack ER, Lee J, Song W, Dabrow M, Brody M, Tuttle H, Hudes G, University of Pennsylvania,263
Commentary on “Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04–75.” Hahn NM, Stadler WM, Zon RT, Waterhouse D, Picus J, Nattam S, Johnson CS, Perkins SM, Wad270
Commentary on “Predicting metastasized seminoma using gene expression.” Ruf CG, Linbecker M, Port M, Riecke A, Schmelz HU, Wagner W, Meineke V, Abend M, Department of Urology, Federal Armed Forces Hospital, Hamburg, Germany : BJU Int 2012;110:E14271
Commentary on “Predicting metastasized seminoma using gene expression.” Ruf CG, Linbecker M, Port M, Riecke A, Schmelz HU, Wagner W, Meineke V, Abend M, Department of Urology, Federal Armed Forces Hospital, Hamburg, Germany : BJU Int 2012;110:E14278
Commentary on “Prognostic significance of undetectable ultrasensitive prostate-specific antigen nadir after radical prostatectomy”: Hong SK, Park HZ, Lee WK, Kim DS, Lee JS, Doo SH, Jeong SJ, Yoon CY, Byun SS, Lee SE, Department of Urology, Seoul National280
Commentary on “Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: Mortality results after 13 years of follow-up”. Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR, Fouad MN, Isaacs287
Commentary on “Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and Ki67 labeling in prostate cancer patients.” Wagner D, Trudel D, Van der Kwast T, Nonn L, Giangreco AA, Li D, Dias A, Cardoza M, Laszlo S, Hersey K, K288
Commentary on “Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and Ki67 labeling in prostate cancer patients.” Wagner D, Trudel D, Van der Kwast T, Nonn L, Giangreco AA, Li D, Dias A, Cardoza M, Laszlo S, Hersey K, K291
Commentary on “Reproductive factors and kidney cancer risk in 2 US cohort studies, 1993-2010.” Karami S, Daugherty SE, Schonfeld SJ, Park Y, Hollenbeck AR, Grubb RL 3rd, Hofmann JN, Chow WH, Purdue MP, Occupational and Environmental Epidemiology Branch, D296
Commentary on “Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome.” Win AK, Lindor NM, Young JP, Macrae FA, Young GP, Williamson E, Parry S, Goldblatt J, Lipton L, Winship I, Leggett B, Tucker KM, Giles GG, Buchanan DD, Cl297
Commentary on “Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome.” Win AK, Lindor NM, Young JP, Macrae FA, Young GP, Williamson E, Parry S, Goldblatt J, Lipton L, Winship I, Leggett B, Tucker KM, Giles GG, Buchanan DD, Cl308
Commentary on “Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study.” Schutz FA, Pomerantz MM, Gray KP, Atkins MB, Rosenberg JE, Hirsch MS, McDermott DF, Lampron ME, Lee GS, Signoretti S, Kantoff PW, Freedman ML,309
Commentary on “Sipuleucel-T immunotherapy for castration-resistant prostate cancer”. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigator311
Commentary on “Smoking negatively affects renal cell carcinoma overall and cancer-specific survival.” Kroeger N, Klatte T, Birkhäuser FD, Rampersaud EN, Seligson DB, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ, Institute of Urologic Oncology, D325
Commentary on “Testicular cancer survivorship: Research strategies and recommendations”. Travis LB, Beard C, Allan JM, Dahl AA, Feldman DR, Oldenburg J, Daugaard G, Kelly JL, Dolan ME, Hannigan R, Constine LS, Oeffinger KC, Okunieff P, Armstrong G, Wiljer329
Commentary on “The clinical epidemiology of urachal carcinoma: Results of a large, population based study.” Bruins HM, Visser O, Ploeg M, Hulsbergen-van de Kaa CA, Kiemeney LA, Witjes JA, Department of Urology, Radboud University Medical Centre, Utrecht,330
Commentary on “The clinical epidemiology of urachal carcinoma: Results of a large, population based study.” Bruins HM, Visser O, Ploeg M, Hulsbergen-van de Kaa CA, Kiemeney LA, Witjes JA, Department of Urology, Radboud University Medical Centre, Utrecht,357
Commentary on “Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma.” Choueiri TK, Lim ZD, Hirsch, MS, Tamboli P, Jonasch E, McDermott DF, Dal Cin P, Corn P, Vaishampayan U, He372
Commentary on Bevacizumab plus interferonα compared with interferonα monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206: Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P, Dutch380
Commentary on Circulating microRNAs as stable blood-based markers for cancer detection: Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, OʹBriant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen, Stire386
Commentary on Cumulative association of five genetic variants with prostate cancer: Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G, Adami HO, Hsu FC, Zhu Y, Bنlter K, Kader AK, Turner AR, Liu W, Bleecker ER, Meyers DA, Duggan D, Carpten JD, Chang BL403
Commentary on Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): An open randomized phase III trial: Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, Lund JA, Tasdemir I, Hoyer M, Wiklu404
Commentary on Essential roles of PI(3)K-p110β in cell growth, metabolism, and tumorigenesis: Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S, Loda M, Roberts TM, Zhao JJ, Department of Cancer Biology, Dana-Farber Cancer Institute, Bos412
Commentary on Flexible robotic retrograde renoscopy: Description of novel robotic device and preliminary laboratory experience: Desai MM, Aron M, Gill IS, Pascal-Haber G, Ukimura O, Kaouk JH, Stahler G, Barbagli F, Carlson C, Moll F, Section of Laparoscop414
Commentary on Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer: Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, Brenner JC, Yu J, Kim JH, Han B, Tan P, Kuma417
Commentary on High-intensity focused ultrasound for prostate cancer: Comparative definitions of biochemical failure: Blana A, Brown SC, Chaussy C, Conti GN, Eastham JA, Ganzer R, Murat FJ, Pasticier G, Rebillard X, Rewcastle JC, Robertson CN, Thuroff S, W434
Commentary on Laboratory evaluation of laparoscopic vascular clamps using a load-cell device—are all clamps the same?: Lee HJ, Box GN, Abraham JB, Elchico ER, Panah RA, Taylor MB, Moskowitz R, Deane LA, McDougall EM, Clayman RV, Department of Urology, Uni435
Commentary on Lack of comprehension of common prostate cancer terms in an underserved population: Kilbridge KL, Fraser G, Krahn M, Nelson EM, Conaway M, Bashore R, Wolf A, Barry MJ, Gong DA, Nease RF Jr., Connors AF, Massachusetts General Hospital, Genera449
Commentary on Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis: Liang XJ, Meng H, Wang Y, He H, Meng J, Lu J, Wang PC, Zhao Y, Gao X, Sun B, Chen C, Xing G, Shen D, Gottesman MM, Wu Y, Yin JJ, Jia L, Chin453
Commentary on Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer: Margulis V, Lotan Y, Karakiewicz PI, Fradet Y, Ashfaq R, Capitanio U, Montorsi F, Bastian PJ, Nielsen ME, Müller SC, Riga467
Commentary on Pelvic Lymph Node Dissection in Prostate Cancer: Briganti A, Blute ML, Eastham JH, Graefen M, Heidenreich A, Karnes JR, Montorsi F, Studer UE, Department of Urology, Vita-Salute University, Milan, Italy470
Commentary on Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer: Morris MJ, Huang D, Kelly WK, Slovin SF, Stephenson RD, Eicher C, Delacruz A, Curley T, Schwartz LH, Scher HI, Genitourinary478
Commentary on Prostate cancer severity among low income, uninsured men: Miller DC, Litwin MS, Bergman J, Stepanian S, Connor SE, Kwan L, Aronson WJ, Department of Urology, University of California, Los Angeles, CA484
Commentary on Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis: Xie D, Gore C, Liu J, Pong RC, Mason R, Hao G, Long M, Kabbani W, Yu L, Zhang H, Chen H, Sun X, Boothman DA, Min W, Hsieh JT, Department of Uro488
Commentary on Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: An expanded-access trial: Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Hariharan S, Lee SH, Haanen J, Castellano D, Vrdoljak E, Schِffski P, Mainwarin491
Commentary on Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer: Attard G, Reid AH, AʹHern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D497
Commentary on Specific reduction of Fas-associated protein with death domain (FADD) in clear cell renal cell carcinoma: Xu H, He L, Feng X, Kapoor A, Tang D, Department of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China501
Commentary on Surgery for metastatic urothelial carcinoma with curative intent: The German experience (AUO AB 30/05): Lehmann J, Suttmann H, Albers P, Volkmer B, Gschwend JE, Fechner G, Spahn M, Heidenreich A, Odenthal A, Seif C, Nürnberg N, Wülfing C, Gr502
Commentary on Surgical resection of renal cell carcinoma after targeted therapy: Thomas AA, Rini BI, Stephenson AJ, Garcia JA, Fergany A, Krishnamurthi V, Novick AC, Gill IS, Klein EA, Zhou M, Campbell SC, Glickman Urological and Kidney Institute, Clevela503
Commentary on Surgical salvage of renal cell carcinoma recurrence after thermal ablative therapy: Nguyen CT, Lane BR, Kaouk JH, Hegarty N, Gill IS, Novick AC, Campbell SC, Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, O507
Commentary on Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model: Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C, Abate-Shen510
Commentary on Testis-sparing surgery versus radical orchiectomy in patients with Leydig cell tumors: Loeser A, Vergho DC, Katzenberger T, Brix D, Kocot A, Spahn M, Gerharz EW, Riedmiller H, Department of Urology, Institute of Pathology, Julius-Maximilians541
Commentary on Transcriptome sequencing to detect gene fusions in cancer: Maher CA, Kumar-Sinha C, Cao X, Kalyana-Sundaram S, Han B, Jing X, Sam L, Barrette T, Palanisamy N, Chinnaiyan AM, Michigan Center for Translational Pathology, Ann Arbor, MI542
Commentary on Urinary collecting system invasion is an independent prognostic factor of organ confined renal cell carcinoma: Verhoest G, Avakian R, Bensalah K, Thuret R, Ficarra V, Artibani W, Tostain J, Guille F, Cindolo L, De La Taille A, Abbou CC, Salo544
Commentary on Use of high fidelity operating room simulation to assess and teach communication, teamwork, and laparoscopic skills: Initial experience: Gettman MT, Pereira CW, Lipsky K, Wilson T, Arnold JJ, Leibovich BC, Karnes RJ, Dong Y, Departments of U546
Commentary on Variation in KLK genes, prostate-specific antigen and risk of prostate cancer: Ahn J, Berndt SI, Wacholder S, Kraft P, Kibel AS, Yeager M, Albanes D, Giovannucci E, Stampfer MJ, Virtamo J, Thun MJ, Feigelson HS, Cancel-Tassin G, Cussenot O,551
Commentary on: “Blood transfusions in radical prostatectomy: A contemporary population-based analysis”. J. Schmitges, M. Sun, F. Abdollah, Q.D. Trinh, C. Jeldres, L. Budäus, M. Bianchi, J. Hansen, T. Schlomm, P. Perrotte, M. Graefen, P.I. Karakiewicz, Mar553
Commentary on: “Long-term functional outcomes after treatment for localized prostate cancer.” Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Potosky AL, Stanford JL, Stroup AM, Van Horn RL, Penson DF. Department of Urologi959
Comments on ‘Sequence surfaces and paleobathymetric trends in Albian to Maastrichtian sediments of Ariyalur area, Cauvery Basin, India’ from Nagendra, Kannan, Sen, Gilbert, Bakkiaraj, Reddy, and Jaiprakash (Marine and Petroleum Geology, 2010, doi:10.1016/